Product Details

These film-coated tablets meet British Pharmacopoeia standards, delivering dependable blood glucose control. Physicians widely prescribe this fixed-dose combination to manage type 2 diabetes, especially when metformin alone doesn’t achieve adequate glycaemic control.

The tablets combine:

• Metformin Hydrochloride BP (500 mg) — a biguanide that reduces hepatic glucose production and improves insulin sensitivity in peripheral tissues
• Glimepiride BP (2 mg) — a sulfonylurea that stimulates the pancreas to release more insulin, further supporting blood glucose control

Together, these two mechanisms complement each other. As a result, VERMET-G offers more comprehensive glycaemic control than either agent alone. Because it addresses both hepatic glucose output and insulin secretion, physicians often prescribe it for patients who need step-up therapy or who haven’t responded fully to metformin monotherapy. Therefore, doctors rely on it across hospitals, diabetology clinics, and general outpatient settings.

Key Features

• Meets BP (British Pharmacopoeia) standards for consistent quality
• Combines a biguanide with a sulfonylurea for dual-action glycaemic control
• Delivers improved stability and easy swallowing through its film coating
• Ensures accurate, validated dosing in every batch
• Suits pharmacy, hospital, and institutional supply needs
• Follows GMP-compliant manufacturing processes